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Ⅰ. INTRODUCTION
Juvenile xanthogranuloma (JXG) is a rare non-Langerhans 
type histiocytosis, that arises in the 1st and 2nd decade1). JXG 
has been earlier referred to as nevoxanthoendothelioma, 
because this xanthoma complex displayed as circumscribed, 
colored, chronic skin lesions composed of oval endothelial- 
like cells with various ranges of vascularity2,3). It was later 
classified as a benign histiocytic disorder most likely of 
dermal dendritic cell origin, but the specific histiocytic 
lineage is still controversial4-6). 
JXG is a pediatric disease with 45~71.0% of the cases 
diagnosed before the age 11,7). The majority of JXG are 
cutaneous lesions. It is most common in the head and neck 
region, closely followed by the extremities and trunk1,7,8). 
Over 80% of the cutaneous JXG cases are solitary with a 
nearly 1:1 sex ratio, male being slightly more prevalent1,7). 
Whereas in multiple cutaneous lesions, 9 in 10 are male1). 
Extracutaneous lesions, especially those without a concurrent 
cutaneous lesion are extremely rare and have been seen 
most commonly in the submucosa and bone of the head 
and neck. Systemic visceral involvement may accompany 
the cutaneous lesions and are seen in the central nervous 
system, eye, lung, liver, pancreas, spleen, kidney, intestines 
and others1,7,9,10). Lesions are well circumscribed, firm nodules 
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Juvenile xanthogranuloma (JXG) is a benign histiocytosis that occurs in the pediatric population. Cutaneous JXG is the most common
form, while extracutaneous lesions, including oral JXG, is extremely rare. Cutaneous JXG can occur as multiple lesions and may have
systemic visceral involvement, but this is not seen in oral JXG. In this case, we report a solitary oral JXG at the gingiva in a 3-year
old male.
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with a yellow to reddish color. In this case, we report a 
solitary oral JXG at the posterior mandibular gingiva in a 
3-year old male. 
Ⅱ. CASE REPORT  
A 3-year-old male patient was referred from the 
Department of Pediatric Dentistry for a recently noticed soft 
tissue mass at the left posterior mandibular gingiva. His 
mother stated that she had accidentally discovered the mass 
three days before the initial visit and that her child had not 
complained of pain or discomfort. She informed us that the 
patient had a fever about a week before the visit. There 
were no other known underlying diseases. The lesion was 
a firm reddish mass surrounding the left primary mandibular 
second molar (#75) with a smooth surface and bleeding by 
palpation (Fig. 1A). It had a diameter of 1.5cm at the longest 
direction. There was no bone erosion on the periapical view 
or computed tomography (CT) (Fig. 2A, B and C). The 
clinical impression was pyogenic granuloma, odontogenic 
fibroma or ossifying fibroma. Excisional biopsy was performed 
with a supraperiosteal incision, including a portion of 
normal tissue around the lesion (Fig. 1B).
Histopathological evaluation of the lesion revealed a 
submucosal mass composed of oval to polygonal cells 
intermixed with giant cells, inflammatory cells and minimal 
stromal tissue (Fig. 3A, B). The lesion cells had a round, 
bland nucleus and homogenous eosinophilic cytoplasm. 
Among those, some of the lesion cells had a finely vacuolated, 
foamy cytoplasm. The lesion cells lacked cohesiveness and 
did not show cellular atypia. The lesion cells had an 
epithelioid morphology, so immunohistochemistry was 
performed to distinguish the origin of the lesion cells. 
Antibody staining of cytokeratin AE1/AE3 (for epithelial 
tumors), CD45 (for lymphocytic tumor), desmin (for muscle 
origin tumor), CD68, CD1a, S-100 (for histiocytosis, Fig. 3C, 
Fig. 1. Clinical image of oral juvenile xanthogranuloma (JXG). 
A. JXG was a solitary reddish round mass surrounding 
the primary mandibular second molar. The excessive 
bleeding was caused by palpation. B. Excised JXG specimen. 
The size of the specimen appeared smaller than the 
original lesion, because of tension loss.
Fig. 2. Radiologic image of the lesion (yellow arrow).
A. Periapical view of lesion located at the posterior of 
the primary mandibular second molar. B. Computed 
tomography (CT) coronal view. C. CT axial view. The 
cortical bone near the lesion does not show signs of 
erosion or resorption.
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3D, and 3E, respectively) and CD31 (for vascular tumors, 
Fig. 3F) were done. Epithelial tumors and muscle origin 
tumors were ruled out due to the cytokeratin and desmin- 
negative pattern, respectively in lesion cells. CD31 stain 
patterns were focally positive and patchy, so we considered 
the possibility of epithelioid hemangioendothelioma, but 
zonal patterns were not definite and stain patterns were 
weak. The lesion cells were CD68-positive and CD1a- 
negative which indicated a histiocytic origin but excluded 
Langerhans cell histiocytosis (LCH). They were focally S-100 
positive and CD45-negative (which was positive in reactive 
lymphocytes). Comprehensive judgement of the clinical and 
pathological findings concluded the final diagnosis as 
juvenile xanthogranuloma (JXG). The associated giant cells 
were Touton type, which supported the diagnosis. The JXG 
lesion was proved anaplastic lymphoma kinase (ALK)-negative 
and BRAF wild type by additional immunohistochemistry. 
The patient was evaluated at a systemic basis, particularly 
the ocular region. The mother of the patient informed the 
staff that the child had been treated for a skin disease right 
after birth until he was 6-month old. The ophthalmologist 
confirmed no signs of JXG in the ocular region. Positron 
Emission Tomography (PET)/CT results were of normal range. 
Healing status was normal 2 months after operation and 
additional surgical procedures were not proceeded (Fig. 4). 
Fig. 3. Histopathologic examination and molecular pathology results of the surgical specimen. 
A. Submucosal infiltrate of lesion cells (Hematoxylin and eosin [HE], original magnification x12.5). B. Oval to polygonal histiocytes 
with eosinophilic cytoplasm, Touton giant cells (inset) and mixed inflammatory cells, mainly lymphocytes. A portion of the 
histiocytes have pale and foamy cytoplasm (yellow arrow) (HE, original magnification x400, inset x400). C. The infiltrated lesion
cells were CD68-positive, indicating a histiocyte origin (Immunohistochemistry [IHC], CD68, original magnification x400). D. The 
histiocytes were CD1a-negative (IHC, CD1a, original magnification x400) E. Focal areas of the histiocytes were S-100-positive 
(IHC, S-100, original magnification x400). F. A few histiocytes were weak CD31-positive (green arrow) (IHC, CD31, original 
magnification x400).
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Ⅲ. DISCUSSION
Histiocytoses are a wide spectrum of disorders with 
accumulation of histiocyte-derived cells. The included subtypes 
range from an indolent reactive form to an aggressive, 
malignant tumor. The initial classification of histiocytic disorders 
in children was given in 1987 by the Working Group of 
the Histiocyte Society11). The disorders were categorized 
into 3 groups (LCH, mononuclear phagocytes other than LC, 
and malignancies). In 2016, Emile et al. proposed a revised 
classification for histiocytic disorders modified with newly 
recognized entities by molecular pathology that categorized 
them into 5 groups (LC-derived, cutaneous and mucocutaneous, 
malignancies, Rosai-Dorfman disease, and hemophagocytic 
lymphohistiocytosis/macrophage activation syndrome)12). By 
their criteria, JXG belongs to the xanthogranuloma family in 
the cutaneous and mucocutaneous histiocytosis group along 
with adult xanthogranuloma (AXG), solitary reticulohistiocytoma, 
benign cephalic histiocytosis, generalized eruptive histiocytosis 
and progressive nodular histiocytosis, with JXG being the 
most common one. In previous literatures, JXG and AXG 
have not been well distinguished and the term “Juvenile” 
has been used regardless of age13).     
The diverse origin of histiocytic disorders can be confirmed 
by immunohistochemical stain pattern combination. Bone 
marrow-derived tissue macrophages commonly express 
CD14 and CD68. LCs are CD1a, langerin (CD207)-positive 
and CD14-negative14). Factor ⅩⅢa is expressed in dermal 
dendritic cells and activated macrophages4,15). In addition to 
factor ⅩⅢa, dermal dendritic cells are CD68-positive and 
CD1a, langerin-negative14). JXG belongs to the non-LC 
group and is believed to be derived from macrophages, 
dermal dendritic cells, or plasmacytoid monocytes4-6). We 
used a combination of CD68, CD1a and S-100 to prove the 
histiocytic lineage of our lesion and distinguish it from other 
histiocytic lesions, such as LCH. The CD68-positive and 
CD1a-negative expression pattern was consistent with JXG. 
S-100 is known to show various levels of expression in 
histiocytic disorders, and is generally negative or weak in 
JXG4,14,16). In our lesion, we observed a focal positive 
pattern in the lesion cells. Recently, it has been known that 
CD31 is possible of positive stain in certain macrophages 
and the results have misinterpreted histiocytic lesions or 
intratumoral macrophages as vascular origin17). In a few 
studies, CD31-positive patterns have been observed in 
about 45% of solitary JXG cases and exhibit a weaker and 
granular stain compared to endothelial cells or vascular 
tumors4). Our case was focal and weak CD31-positive, with 
most of the stained cells positioned near the endothelial 
cells at the blood vessels which gave confusion as a 
vascular tumor at first sight.          
Cutaneous JXG is the predominant type, so the clinical 
manifestations mentioned in our introduction are relevant to 
cutaneous cases. Although there were not sufficient numbers 
of oral cases, several differences of oral and cutaneous JXG 
has been reviewed. Compared to the majority of cutaneous 
JXG cases occurring before the age 1, only 14% of the oral 
JXG cases were diagnosed in the 1st decade1,7,18). Oral JXG 
has been observed at the tongue, gingiva, palate, lips, and 
Fig. 4. Clinical image of the oral cavity 2 months after the previous
excision. Healing was favorable and there were no signs 
of recurrence.
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buccal mucosa13,18). Near to 90% of oral JXG cases are 
solitary, and systemic JXG has not been reported in oral 
JXG18). Our patient was examined of the entire body and 
particularly the eye, in case of systemic lesions. Visceral 
involvement results in complications and poor prognosis. 
Furthermore, ocular JXG can lead to glaucoma and other 
severe vision problems10). In previous literature, oral lesions 
have only been accompanied with cutaneous lesions. 
Importantly, cutaneous JXG is known to progress with 
indolent clinical behavior and result in spontaneous regression. 
Unfortunately, this is not the case for extracutaneous JXG. 
Surgical excision is required, and incomplete removal can 
lead to recurrence13). Oral JXG has been reported to have 
a recurrence rate of 14%18). A periodic follow up is 
recommended, as there have been cases that have recurred 
after 1 to 7 months after surgical excision13).          
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